General MedicationsORALGeneric

PARCOPA

CARBIDOPA; LEVODOPA

Standard Dose

25MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Max Dose

Refer to approved labeling

Primary Use

Marketing status: Discontinued

Summary

Approval overview PARCOPA is listed in Drugs@FDA under application 076699 (ANDA).

Marketing status: Discontinued Active ingredient CARBIDOPA; LEVODOPA Form and strength TABLET, ORALLY DISINTEGRATING;ORAL - 25MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor UCB INC Submission history Latest submission status date: 2010-12-30 00:00:00.

Structured Monograph

Clinical summary

Approval overview PARCOPA is listed in Drugs@FDA under application 076699 (ANDA). Marketing status: Discontinued Active ingredient CARBIDOPA; LEVODOPA Form and strength TABLET, ORALLY DISINTEGRATING;ORAL - 25MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor UCB INC Submission history Latest submission status date: 2010-12-30 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued

Interaction Notes

No interaction notes stored yet.